Century Therapeutics, Inc. (IPSC) stock
IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.65+0.02 (+1.23%)
Close on Nov 13, 2026Market cap $298.77MP/E –Yield –
Century Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Century Therapeutics's operating margin for the twelve months ending Dec 31, 2025 was -15.8%. For fiscal 2025 it was -15.8%, against -2096.5% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -15.8% | +2080.7 |
| FY2024 | Dec 31, 2024 | -2096.5% | +4460.4 |
| FY2023 | Dec 31, 2023 | -6556.9% | −3982.7 |
| FY2022 | Dec 31, 2022 | -2574.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | 67.9% | +3729.8 |
| Q4 FY2024 | Dec 31, 2024 | -893.5% | +15435.6 |
| Q3 FY2024 | Sep 30, 2024 | -4398.1% | +19673.5 |
| Q2 FY2024 | Jun 30, 2024 | -4507.8% | +30923.5 |
| Q1 FY2024 | Mar 31, 2024 | -3661.9% | −1796.7 |
| Q4 FY2023 | Dec 31, 2023 | -16329.1% | −9936.4 |
| Q3 FY2023 | Sep 30, 2023 | -24071.6% | −22644.6 |
| Q2 FY2023 | Jun 30, 2023 | -35431.3% | −33185.5 |
| Q1 FY2023 | Mar 31, 2023 | -1865.2% | +1673.2 |
| Q4 FY2022 | Dec 31, 2022 | -6392.7% | – |
| Q3 FY2022 | Sep 30, 2022 | -1427.1% | – |
| Q2 FY2022 | Jun 30, 2022 | -2245.8% | – |
| Q1 FY2022 | Mar 31, 2022 | -3538.4% | – |
See a number that looks wrong?